Skip to main content
SpringerLink
Log in

What Is Certain in the Treatment with Immunoglobulins?

  • Chapter
Sepsis

Part of the book series: Update in Intensive Care and Emergency Medicine ((UICM,volume 18))

Abstract

Almost a century ago, in the time of von Behring, Ehrlich and Roux, the beneficial and in many cases live-saving concept of passive immunization with toxin- or pathogen-specific antisera was born and put into practice in Europe. The concept of passive immunotherapy and immunoprophylaxis against bacterial infections, although obviously efficacious, has been superseded by antimicrobial therapy with a continuously growing number of antibiotic agents. Interestingly enough, intramuscular immunoglobulins continue to be widely used in the prophylaxis and treatment of viral diseases such as measles, mumps, varicella, rubella and hepatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ehrlich P (1891) Experimentelle Untersuchungen über Immunität, I. über Ricin; II. über Abrin. Dtsch Med Wochenschr 17:976–979; 1218-1219

    Article  Google Scholar 

  2. von Behring E, Kitasato (1890) Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Tieren. Dtsch Med Wochenschr 16:1113–1114

    Article  Google Scholar 

  3. Karelitz S (1938) Prophylaxis against measles with the globulin fraction of immune adult serum. Am J Dis Child 55:768–775

    Google Scholar 

  4. Tiselius A, Kabat EA (1938) Electrophoresis of immune serum. Science 87:416–417

    Article  PubMed  CAS  Google Scholar 

  5. Cohn EJ, Luetscher JA Jr, Oncley JL et al (1940) Preparation and properties of serum and plasma proteins. J Am Chem Soc 62:3396–3400

    Article  CAS  Google Scholar 

  6. Schultze HE, Schwick G (1962) Über neue Möglichkeiten intravenöser Gammaglobulin-Applikation. Dtsch Med Wochenschr 87; 1643–1650

    Article  PubMed  CAS  Google Scholar 

  7. Barandun S, Isliker H (1986) Development of immunoglobulin preparations for intravenous use. Vox Sang 51:157–160

    Article  PubMed  CAS  Google Scholar 

  8. Gronski P, Hofstaetter T, Kanzy EJ et al (1983) S-sulfonation: a reversible chemical modification of human immunoglobulins permitting intravenous application. I. Physiochemical and binding properties of S-sulfonated and reconstituted IgG. Vox Sang 45:144–154

    CAS  Google Scholar 

  9. Morell A (1986) Various immunoglobulin preparations for intravenous use. Vox Sang 51[Suppl 2]:pp 44–49

    Article  PubMed  Google Scholar 

  10. Römer J, Morgenthaler JJ, Scherz R, Skvaril F (1982) Characterization of various immunoglobulin preparations for intravenous application. Vox Sang 42:62–73

    PubMed  Google Scholar 

  11. Schroeder DD, Tankersley DL, Lundblad JL (1981) A new preparation of modified immune serum globulin (human) suitable for intravenous administration. Vox Sang 40:373–394

    Article  PubMed  CAS  Google Scholar 

  12. Stephan W (1969) Beseitigung der Komplementfixierung von Gammaglobulin durch chemische Modifizierung mit β-Propiolacton. Z Klin Chem Klin Biochem 7:282–286

    PubMed  CAS  Google Scholar 

  13. Stephan W (1975) Undegraded human immunoglobulin for intravenous use. Vox Sang 28:422–437

    Article  PubMed  CAS  Google Scholar 

  14. Stephan W (1980) Intravenöse Immunglobuline. Proteinchemische und immunbiologische Charakterisierung der verschiedenen Präparatetypen. Arzneimittelforschung/ Drug Res 30:116–117

    Google Scholar 

  15. Schreiber JR, Barrus VA, Siber GR (1985) Decreasd protective efficacy of reduced and alkylated human immune serum globulin in experimental infection with Haemophilus influenzae type b. Infect Immun 47:142–148

    PubMed  CAS  Google Scholar 

  16. Stephan W, Dichtelmüller H (1984) Reduced efficacy of sulfitolysed intravenous immunoglobulin. Eur J Clin Microbiol 3:47

    Article  PubMed  CAS  Google Scholar 

  17. van Furth R, Leijh PCJ, Klein F (1984) Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use. J Infect Dis 149:511–517

    Article  PubMed  Google Scholar 

  18. Stephan W, Dichtelmüller H, Schedel I (1985) Properties and efficacy of a human immunoglobulin M preparation for intravenous administration. Arzneimittelforschung/ Drug Res 35:933–936

    CAS  Google Scholar 

  19. Berger D, Beger HG (1990) Adjuvant septic therapy with immunoglobulin — in vivo and in vitro studies. Intensive Care Med 16[Suppl 1]:20

    Google Scholar 

  20. Garbett ND, Munro CS, Cole PJ (1989) Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with Sandoglobulin. Clin Exp Immunol 76:8–12

    PubMed  CAS  Google Scholar 

  21. McCabe WR, DeMaria A Jr, Berberich H, Johns MA (1988) Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R 595 (Re chemotype) mutant. J Infect Dis 158:291–300

    Article  PubMed  CAS  Google Scholar 

  22. Collins MS, Roby RE (1984) Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Am J Med 76:168–174

    Article  PubMed  CAS  Google Scholar 

  23. Collins MS, Hector RF, Roby RE et al (1987) Prophylaxe gramnegativer und grampositiver Infektionen mit drei intravenösen Immunglobulin-Präparaten und Therapie der experimentellen polymikrobiellen Verbrennungssepsis mit intravenösem Pseudomonas-Immunglobulin G und Ciprofloxacin im Tiermodell. Infection 15[Suppl 2]:51–59

    Article  Google Scholar 

  24. Ferreira A, Garcia Rodriguez MC, Fontan G (1989) Follow-up of anti-IgA antibodies in primary immunodeficient patients treated with γ-globulin. Vox Sang 56:218–222

    Article  PubMed  CAS  Google Scholar 

  25. Winter PM, Manndorff P (1988) The frequency of IgA-deficiency in the Austrian population. Infusionstherapie 15:221–224

    PubMed  CAS  Google Scholar 

  26. Björkander J, Cunningham-Rundles C, Lundin P et al (1988) Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 84:107–111

    Article  PubMed  Google Scholar 

  27. Centers for Disease Control (1986) Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathyassociated virus infection. MMWR 35:231–233

    Google Scholar 

  28. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med 319:902–907

    Article  Google Scholar 

  29. John TJ, Ninan GT, Rajagopalan MS et al (1979) Epidemic hepatitis B caused by commercial human immunoglobulin. Lancet 1:1074

    Article  PubMed  CAS  Google Scholar 

  30. Lever AML, Brown D, Webster ADB, Thomas HC (1984) Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 2:1062–1064

    Article  PubMed  CAS  Google Scholar 

  31. Ochs HD, Fischer SH, Virant FS et al (1985) Non-A, non-B hepatitis and intravenous immunnoglobulin. Lancet 1:404–405

    Article  Google Scholar 

  32. Wells MA, Wittek AE, Epstein JS et al (1986) Inactivation and partition of human T-cell lymphotropic virus, type III, during ethanol fractionation of plasma. Transfusion 26:210–213

    Article  PubMed  CAS  Google Scholar 

  33. Yap PL (1988) Hepatitis transmission by blood products. J Hosp Infect 11[Suppl A]:166–174

    Article  PubMed  Google Scholar 

  34. Alexander JW, Stinnett JD, Ogle CK et al (1979) A comparison of immunologic profiles and their influence on bacteremia in surgical patients with a high risk of infection. Surgery 86:94–104

    PubMed  CAS  Google Scholar 

  35. Zimmerli W (1985) Impaired host defence mechanisms in intensive care unit patients. Intensive Care Med 11:174–178

    PubMed  CAS  Google Scholar 

  36. Marodi L, Kalmar A, Szabo I (1989) Opsonic activity in serum from septic infants treated with intravenous immunoglobulin. Arch Dis Child 64:530–534

    Article  PubMed  CAS  Google Scholar 

  37. Dalhoff A (1984) Synergy between acylureidopenicillins and immunoglobulin G in experimental animals. Am J Med 76:91–100

    Article  PubMed  CAS  Google Scholar 

  38. Dalhoff A (1984) In vitro and in vivo effect of immunoglobulin G on the integrity of bacterial membranes. Infection 12:214–222

    Article  PubMed  CAS  Google Scholar 

  39. Offenbartel KS, Christensen P, Gullstrand P, Prellner K (1986) Synergism between gammaglobulin prophylaxis and penicillin treatment in experimental post-splenectomy sepsis in the rat. Int Arch Allery Appl Immunol 79:45–48

    Article  Google Scholar 

  40. Cunningham-Rundles C, Siegal FP, Smithwick EM et al (1984) Efficacy of intravenous immunoglobulin in primary immunodeficiency disease. Ann Intern Med 101:435–439

    PubMed  CAS  Google Scholar 

  41. Kark JD, Witztum E, Mazkin H et al (1984) The three-year incidence of non-B viral hepatitis morbidity in a controlled trial of pre-exposure immune serum globulin prophylaxis. Infection 12:251–255

    Article  PubMed  CAS  Google Scholar 

  42. Ohara H, Ebisawa I, Ohtani S (1986) Prophylactic efficacy of immune serum globulin against hepatitis A. Jpn J Exp Med 56:229–233

    PubMed  CAS  Google Scholar 

  43. Sorenson RU, Polmar SH (1984) Efficacy and safety of high-dose intravenous immune globulin therapy for antibody deficiency syndromes. Am J Med 76[Suppl 3A]:83–90

    Article  Google Scholar 

  44. Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338:732–736

    Article  PubMed  CAS  Google Scholar 

  45. Dwyre JM (1992) Manipulating the immune system with immune globulin. N Engl J Med 326:107–116

    Article  Google Scholar 

  46. Leung DYM, Burns JC, Newburger JW, Geha RS (1987) Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gamma globulin. J Clin Invest 79:468–472

    Article  PubMed  CAS  Google Scholar 

  47. Mannhalter JW, Eibl MM (1986) Polymeric IgG down modulates antigen presentation by human monocytes. In Eibl MM, Rosen FS (eds) Primary immunodeficiency diseases. Elsevier, Amsterdam, pp 281–286

    Google Scholar 

  48. Mannhalter JW, Ahmad R, Wolf HM, Eibl MM (1987) Effect of polymeric IgG on human monocyte functions. Int Arch Allergy Appl Immunol 82:159–167

    Article  PubMed  CAS  Google Scholar 

  49. Tsubakio T, Kurata Y, Katagiri S et al (1983) Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose γ-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 53:697–702

    PubMed  CAS  Google Scholar 

  50. Pollack M, Young LS (1979) Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest 63:276–286

    Article  PubMed  CAS  Google Scholar 

  51. Baker CJ, Melish ME, Hall RT et al (1992) Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med 327:213–219

    Article  PubMed  CAS  Google Scholar 

  52. Chirico G, Rondini G, Plebani A et al (1987) Intravenous gammaglobulin therapy for prophylaxis of infection in high risk neonates. J Pediatr 110:437–442

    Article  PubMed  CAS  Google Scholar 

  53. Haque KN, Zaidi MH, Haque SK et al (1986) Intravenous immunoglobulin for prevention of sepsis in preterm and low-birth-weight infants. Pediatr Infect Dis 5:622–625

    Article  PubMed  CAS  Google Scholar 

  54. Hill HR, Shigeoka AO, Gonzales LA, Christensen RD (1989) Intravenous immune globulin use in newborns. J Allergy Clin Immunol 84:617–624

    Article  PubMed  CAS  Google Scholar 

  55. Magny JF, Bremard-Oury C, Brault D et al (1991) Intravenous immunoglobulin therapy for prevention of infection in high risk premature infants: report of a multicenter, double-blind study. Pediatrics 88:437–443

    PubMed  CAS  Google Scholar 

  56. Stabile A, Miceli Sopo S, Romanelli V et al (1988) Intravenous immunoglobulin for prophylaxis of neonatal sepsis in premature infants. Arch Dis Child 63:441–443

    Article  PubMed  CAS  Google Scholar 

  57. Bussel JB (1990) Intravenous gammaglobulin in the prophylaxis of late sepsis in very low-birth-weight infants: preliminary results of a randomized, double-blind, placebocontrolled trial. Rev Infect Dis 12[Suppl 4]:S457–S462

    Article  PubMed  Google Scholar 

  58. Clapp DW, Kliegman RM, Baley JE et al (1989) Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study. J Pediatr 115:973–978

    Article  PubMed  CAS  Google Scholar 

  59. Kinney J, Mundorf L, Gleason C et al (1991) Efficacy and pharmakokinetics of intravenous immune globulin administration to high-risk neonates. Am J Dis Child 145:1233–1238

    PubMed  CAS  Google Scholar 

  60. Besa EC (1984) Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med 76[Suppl 3A]:209–218

    Article  PubMed  CAS  Google Scholar 

  61. Gordon DS, Hearn EB, Spira TJ et al (1984) Phase I study of intravenous gamma globulin in multiple myeloma. Am J Med 76[Suppl 3A] 111–116

    Article  PubMed  CAS  Google Scholar 

  62. Schedel I (1983) Intravenöse Immunglobulinsubstitution bei Patienten mit multiplem Myelom, Morbus Waldenström und chronischer lymphatischer Leukämie. In: Schmidt RE, Stroehmann I (eds) Immunglobuline — Grundlagen und klinische Anwendung. Karger, Basel, pp 52–58

    Google Scholar 

  63. Schmidt RE, Hartlapp JH, Niese D et al (1984) Reduction of infection frequency by intravenous gammaglobulins during intensive induction therapy for small cell carcinoma of the lung. Infection 12:167–170

    Article  PubMed  CAS  Google Scholar 

  64. Seybold JD, Bogdahn U, Seubert W, Krauseneck P (1991) 7S-Immunglobulin zur Infektprophylaxe bei Patienten mit malignen Hirntumoren unter zytostatischer Therapie, eine randomisierte prospektive Doppelblindstudie. Onkol Klin 3:38–48

    Google Scholar 

  65. Baumgartner JD, Glauser MP, McCutchan JA et al (1985) Prevention of gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet 2:59–63

    Article  PubMed  CAS  Google Scholar 

  66. Duswald KH, Müller K, Seifert J, Ring J (1980) Wirksamkeit von i. v. Gammaglobulin gegen bakterielle Infektionen chirurgischer Patienten — Ergebnisse einer kontrollierten, randomisierten klinischen Studie. Munch Med Wochenschr 122:832–836

    CAS  Google Scholar 

  67. Glinz W, Grob PJ, Nydegger UE et al (1985) Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma — a randomized, placebo-controlled study. Intensive Care Med 11:288–294

    Article  PubMed  CAS  Google Scholar 

  68. Kress HG, Scheidewig C, Engelhardt W et al (1989) Prediction and prevention, by immunological means, of septic complications after elective cardiac surgery. In: Schlag G, Redl H (eds) 2nd Vienna Shock Forum. Liss, New York, pp 1031–1035

    Google Scholar 

  69. Kress HG, Scheidewig C, Elert O (1990) Postoperative passive immunoprophylaxis prevents infections in “at-risk” patients after open-heart surgery. J Cardiothorac Anesth 4[Suppl 3]:67

    Article  Google Scholar 

  70. The Intravenous Immunoglobulin Collaborative Study Group (1992) Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 327:234–240

    Article  Google Scholar 

  71. Kress HG, Gehrsitz P, Elert O (1987) Predictive value of skin testing, neutrophil migration and C-reactive protein for postoperative infections in cardiopulmonary bypass patients. Acta Anaesthesiol Scand 31:397–404

    Article  PubMed  CAS  Google Scholar 

  72. Calandra T, Glauser M, Schellekens J, Verhoef J (1988) Treatment of gram-negative spetic shock with human IgG antibody to Escherichia coli J5: a prospective, double blind, randomized trial. J Infect Dis 158:312–319

    Article  PubMed  CAS  Google Scholar 

  73. Zanetti G, Glauser MP, Baumgartner JD (1991) Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique. Rev Infect Dis 13:985–992

    Article  PubMed  CAS  Google Scholar 

  74. Haque KN, Zaidi MH, Bakahim H (1988) IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child 142:1293–1296

    PubMed  CAS  Google Scholar 

  75. Sidiropoulos D, Böhme U, von Muralt G et al (1981) Immunoglobulinsubstitution bei der Behandlung der neonatalen Sepsis. Schweiz Med Wochenschr 111:1649–1655

    PubMed  CAS  Google Scholar 

  76. Just HM, Metzger M, Vogel W, Pelka RB (1986) Therapeutic effects of immunoglobulin in intensive care patients with severe infections. Klin Wochenschr 64:245–256

    Article  PubMed  CAS  Google Scholar 

  77. Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J (1987) Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 65:1132–1138

    Article  PubMed  CAS  Google Scholar 

  78. Dominioni L, Dionigi R, Zanello M et al (1991) Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 126:236–240

    Article  PubMed  CAS  Google Scholar 

  79. Schedel I, Dreikhausen U, Nentwig B et al (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Grit Care Med 19:1104–1113

    Article  CAS  Google Scholar 

  80. Ziegler EJ, McCutchan JA, Fierer J et al (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225–1230

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. G. Kress
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Anästhesiologie und Intensivtherapie, Klinikum der Friedrich Schiller-Universität Jena, Bachstraße 18, 07740, Jena, Germany

    Konrad Reinhart

  2. Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Steglitz der FU Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    Klaus Eyrich

  3. Department of Anesthesiology and Critical Care Medicine, Hadassah Hebrew University, Medical Center, P. O. Box 12000, 91120, Jerusalem, Israel

    Charles Sprung (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kress, H.G. (1994). What Is Certain in the Treatment with Immunoglobulins?. In: Reinhart, K., Eyrich, K., Sprung, C. (eds) Sepsis. Update in Intensive Care and Emergency Medicine, vol 18. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85036-3_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85036-3_36

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-85038-7

  • Online ISBN: 978-3-642-85036-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation